Now let me verify specific claims from the reviewer. Let me check the Discussion section for the "33 Rosetta scores" inconsistency and the stratification analysis details more carefully.Now I have thoroughly read the paper. Let me compose the draft review based on my verification of the reviewer's claims.Now let me run the calibration search — Round 1 bracketing:Let me read the most relevant anchor papers to calibrate my scoring.Now let me form my Round 1 bracket based on these comparisons.

**Round 1 Bracket Assessment:**

- **Score < 3.5 (Reject)**: ProteinAdapter (3.40), ProteiNexus (3.67) — These had unclear baselines, marginal improvements, and insufficient experimental rigor. ProteinVista is clearly stronger with at least one very strong result (IC₅₀) and a clean controlled comparison.

- **Score 3.5–5.5 (Borderline Reject)**: E³former (5.25), bio2token (5.00) — These share the pattern of interesting ideas with marginal or incomplete evidence. E³former was rejected despite 3×score-6 reviews because of weak motivation and marginal gains.

- **Score 5.5–7.5 (Borderline Accept)**: Protein-ligand binding (5.67), Pre-training Seq/Struct/Surface (5.75), ProteinWorkshop (6.25), SaProt (7.33) — These were accepted with varying degrees of enthusiasm. SaProt had broad evaluation across 10 tasks with consistent improvements.

ProteinVista has one genuinely strong result (IC₅₀), good compute efficiency, honest failure reporting, but overclaims in title/abstract, missing structure-aware baselines, no error bars, and mixed classification evidence. This places it in the **4.5–6.0** range — stronger than the rejected ProteinAdapter/ProteiNexus papers, comparable to E³former, but weaker than accepted papers like SaProt or the Protein-ligand binding paper.

Let me now write the final calibrated review.

---

## Summary
ProteinVista introduces a 3D CNN that voxelizes all heavy atoms in protein structures at 1Å resolution, pretrains on ~500K AlphaFold-2 structures via contrastive alignment with ESM-2 embeddings, and evaluates on enzyme-substrate classification (ESP), transporter-substrate classification (TSP), and IC₅₀ regression for drug-target interactions. The paper claims that this atom-level 3D representation outperforms sequence-only transformers (ESM-2) on structure-dependent tasks while requiring ~5× fewer parameters and ~1% of ESM-2's pretraining GPU-hours.

## Strengths
- **Strong IC₅₀ regression result with rigorous statistical testing.** ProteinVista achieves R²=0.69 vs. ESM-2₆₅₀M's 0.61 (Table 2), a substantial improvement confirmed by Wilcoxon signed-rank test (p < 10⁻³⁰⁴). This is the paper's strongest evidence that atom-level 3D geometry captures binding-relevant information that sequence models miss.

- **Controlled experimental design isolates the protein encoder.** Section 3.1 describes a deliberate setup where both ProteinVista and ESM-2 share identical MolFormer embeddings and the same two-layer prediction head, ensuring observed differences are attributable to the protein encoder. This is a commendable experimental choice.

- **Honest scope delineation via failure mode reporting.** Section 3.4 reports that ProteinVista underperforms ESM-2 on GO term prediction (F_max 0.57 vs. 0.62) and provides a reasonable explanation grounded in the homology-driven nature of GO inference. This candor strengthens the paper's credibility.

- **Informative stratification analysis with nuanced findings.** Figure 2a–c reveals that ProteinVista's advantage concentrates on high-confidence AlphaFold structures and proteins with close training-set relatives — a finding that qualifies rather than merely promotes the headline results.

- **Compute efficiency is concrete and well-documented.** Section 4.3 and Figure 3 provide specific numbers: 20× faster per-protein training throughput vs. ESM-2₆₅₀M on A100, ~1% of pretraining GPU-hours, 5× fewer parameters. The storage trade-off (75 GB for voxelized data vs. 3 MB for sequences for 5,800 proteins) is also honestly reported.

## Weaknesses

### Fatal
None

### Major
- **Title and abstract overclaim relative to the evidence.** The abstract states ProteinVista "outperforms sequence transformers on three benchmarks," but on ESP, ProteinVista achieves 91.8% accuracy vs. ESM-2₆₅₀M's 91.9% (Table 1) — ESM-2 is marginally better on the primary metric. While ProteinVista wins on precision (0.89 vs. 0.86), the result is mixed at best. On TSP, the margin is 1.5 percentage points (90.8% vs. 89.3%). No error bars from multiple random seeds are reported for any benchmark, making these small margins uncertain. The strong IC₅₀ result genuinely supports the title claim, but extending it to all three benchmarks overstates the evidence. The paper's own body text uses the more accurate "surpasses or equals" (Section 3.2), but the title and abstract do not reflect this qualification.

- **Contrastive pretraining against ESM-2 entangles sequence and structure signals, partially undermining the interpretive claim.** The preferred pretraining objective (Section 2.3) explicitly aligns ProteinVista embeddings with ESM-2's, meaning ProteinVista absorbs sequence-level information. The Rosetta-pretrained ablation (Section 4.2) shows only a 1.0% relative decrease in R² on IC₅₀, indicating the structural signal is real. However, this ablation is reported only for IC₅₀ — running the Rosetta-pretrained model on ESP and TSP would cleanly separate contributions across all benchmarks. The paper claims "complementarity" between sequence and structure, but the diminishing returns of the ensemble on IC₅₀ (Table 2: ensemble R²=0.68 < standalone R²=0.69) could reflect redundancy introduced by the contrastive pretraining rather than inherent structural dominance.

- **No comparison against structure-aware baselines.** GearNet, ESM-GearNet, and DeepFRI are discussed in the introduction as motivation, yet none appear as baselines in the experiments. Since ProteinVista's core claim is that atom-level 3D CNNs surpass residue-level representations, a direct comparison against at least one GNN baseline on one benchmark would substantially strengthen the architectural argument. Without it, the paper only demonstrates superiority over sequence-only models, not over other structure-aware approaches.

### Minor
- **Stratification analysis reveals ProteinVista's advantage is in the high-homology regime.** Figure 2a shows that ProteinVista outperforms ESM-2 primarily on high-identity proteins — precisely the regime where simpler homology-transfer methods also work well. In the low-identity regime, where structural signal could uniquely contribute beyond sequence, the models perform comparably. This finding deserves more honest discussion, as it qualifies the claim that 3D structure adds unique value.

- **SOTA comparison (Section 3.3) conflates pipeline engineering with model contribution.** ESM-ProteinVista_OP involves jointly fine-tuning MolFormer, training contrastive networks, and averaging predictions from multiple model variants. The resulting improvements over SPOT (0.8pp accuracy) and ProSmith-ESP (0.2pp accuracy) could plausibly come from the pipeline optimization rather than ProteinVista itself. The controlled comparison in Section 3.2 remains the clean evidence; Section 3.3 weakens rather than strengthens the attributional clarity.

- **Internal inconsistency in Rosetta score count.** Section 2.3 reports pretraining on "23 in silico computed Rosetta scores" while Section 5 says "33 Rosetta scores." One of these is incorrect.

### Trivial
- Notation issue in Section 2.1: the Gaussian density formula "v⃗ = exp(−∥v⃗ − r⃗∥/σ²)" conflates the voxel position with the density value and appears to be missing the squared norm in the exponent.

## Nice-to-Haves
- Testing rotation robustness directly by evaluating under random SO(3) rotations at inference time. The paper uses 48 discrete orientations (octahedral group plus reflections) but claims "rotation-robust representations" — a direct test would validate or reveal the limits of this strategy.
- Analyzing what fraction of proteins are cropped at the 160³ grid boundary and the impact on performance for large proteins.
- Reporting error bars / confidence intervals from multiple random seeds, especially for the close classification results.
- Running the Rosetta-pretrained model (no ESM-2 signal) through ESP and TSP benchmarks to cleanly separate structural from distilled-sequence contributions across all tasks.

## Removed Points
*These points are flagged to be removed, treat them with caution:*

- **Rotation invariance claim "unsupported"**: The paper primarily uses "rotation-robust" in the text (abstract: "rotation-robust representations"), not "rotation-invariant." The figure caption does say "rotational invariance," but this is a caption-level imprecision rather than a core methodological flaw. The practical impact is unclear since the ablation (Section 4.2) shows pretraining augmentation sufficiently stabilizes representations. Moved to nice-to-have.

- **AlphaFold structure generation cost omitted from compute comparison**: AlphaFold structures are publicly available for Swiss-Prot (the primary use case), and requiring structure prediction for new proteins is an inherent property of any structure-based method, not a flaw specific to ProteinVista.

- **Storage requirement as a weakness**: The paper already explicitly acknowledges this trade-off in Section 4.3 and Figure 3d.

- **Absence of error bars as a standalone criticism**: Weakened because single-run evaluation is common in this field's benchmarks. However, the concern is retained as part of the overclaiming major weakness because the specific margins on classification tasks are too small to be meaningful without variance estimates.

## Novel Insights
The stratification analysis (Figure 2a–c) revealing that the 3D CNN's advantage over sequence models concentrates in the high-confidence, high-homology regime — rather than the low-homology regime where one might expect structure to most uniquely contribute — is a genuinely informative finding that challenges naive assumptions about when 3D structural information adds value.

## Suggestions
- Moderate the abstract claim from "outperforms" to "matches or outperforms" for the classification tasks, reserving the outperformance claim for IC₅₀ where the evidence is unambiguous.
- Run the Rosetta-pretrained model through all downstream benchmarks (not just IC₅₀) to cleanly disentangle structural from distilled-sequence contributions.
- Include at least one GNN baseline (e.g., GearNet or ESM-GearNet) on one benchmark to support the atom-level vs. residue-level architectural claim.
- Report multiple-seed variance for classification benchmarks where margins are ≤1.5 percentage points.
- Discuss the stratification findings more honestly, acknowledging that the current evidence shows 3D structure's advantage is concentrated in high-homology settings.

## Score and Decision

### Calibration Anchors

| Paper | Path | Avg Score | Round | Comparison to ProteinVista |
|---|---|---|---|---|
| Time-dependent UMAP | P49gSPmrvN | 1.00 | R1 | Fundamentally flawed; ProteinVista is far stronger |
| IC-Light | u1cQYxRI1H | 10.00 | R1 | Different domain; much stronger contribution |
| Cross-Lingual Robots | gwZ90hFSL2 | 1.00 | R1 | Pseudo-science; not comparable |
| Clothing-Irrelevant ReID | 5lUdTogEL3 | 1.00 | R1 | Fundamentally flawed; ProteinVista is far stronger |
| ProteinAdapter | jqx5XI4Yr3 | 3.40 | R1 | Similar topic, weaker methodology; ProteinVista has stronger standout result |
| 3D Molecular LEGO | rEQ8OiBxbZ | 3.00 | R1 | Similar domain; ProteinVista has cleaner experimental design |
| Ligand Conformation PsiDiff | m9zWBn1Y2j | 3.00 | R1 | Similar domain; ProteinVista has a stronger IC₅₀ result |
| GNNAS-Dock | An87ZnPbkT | 3.00 | R1 | Different focus; both have limited baselines |
| ProteiNexus | iBAWiEjogY | 3.67 | R1 | Similar topic with data leakage concerns; ProteinVista is methodologically cleaner |
| E³former | QKywN4BbqA | 5.25 | R1 | Similar pattern — good idea, marginal improvements, incomplete evidence; comparable quality |
| bio2token | 6ktqrC1Bpf | 5.00 | R1 | Similar quality level; ProteinVista has a stronger standout result |
| Reliable Conditional Diffusion | fM432E7l5w | 3.60 | R1 | Different focus; highly variable reviews |
| Protein-ligand binding (BindNet) | AXbN2qMNiW | 5.67 | R1 | Similar domain; BindNet had flexibility concerns but was accepted; ProteinVista has comparable quality |
| SaProt | 6MRm3G4NiU | 7.33 | R1 | Much broader evaluation, consistent improvements; ProteinVista's evidence is more mixed |
| Pre-training Seq/Struct/Surface | BEH4mGo7zP | 5.75 | R1 | Similar quality — marginal improvements with honest reporting; accepted |
| ProteinWorkshop | sTYuRVrdK3 | 6.25 | R1 | Benchmark contribution (different paper type); accepted with "fair" contribution scores |
| SE(3)-Flow Matching | kJFIH23hXb | 8.00 | R1 | Much stronger, cleaner contribution; ProteinVista is well below this level |
| ProtComposer | 0ctvBgKFgc | 8.00 | R1 | Much stronger novelty and evaluation; ProteinVista is well below |
| Walk-Jump Sampling | zMPHKOmQNb | 8.00 | R1 | Fundamentally stronger contribution with wet-lab validation |
| Never Train from Scratch | PdaPky8MUn | 8.00 | R1 | Different focus but stronger methodological clarity |

**Round 1 bracket: 4.5 – 6.0**

ProteinVista is clearly stronger than the 3.0–3.5 rejected papers (ProteinAdapter, LEGO, ProteiNexus) due to its strong IC₅₀ result, clean controlled comparison, and honest failure reporting. However, it falls below the accepted papers with consistent evidence (SaProt at 7.33, ProteinWorkshop at 6.25). It is most comparable to E³former (5.25, rejected) and the protein-ligand binding paper (5.67, accepted).

**Key factors pushing toward 5.0 (borderline reject):**
- The overclaiming in title/abstract vs. actual evidence is significant
- Missing structure-aware baselines leave the central architectural claim untested
- Classification results are too marginal to support the headline claim
- Contrastive pretraining entanglement is only partially addressed

**Key factors pushing toward 5.5–6.0 (borderline accept):**
- The IC₅₀ result is genuinely strong and statistically rigorous
- Compute efficiency is a real practical contribution
- Honest failure mode reporting and nuanced stratification analysis
- Clean controlled experimental design (Section 3.2)

The paper has real substance but its claims exceed its evidence. The IC₅₀ result alone would support a narrower, honest paper. The overclaiming on classification, missing GNN baselines, and pretraining entanglement push this toward the lower end of the bracket.

**Final score: 5.0** — Between borderline reject and borderline accept, leaning toward reject. The paper has one strong result and good methodology, but the headline claims are broader than the evidence supports, and key comparisons (structure-aware baselines) are missing.

**Decision: Reject** — The core idea and IC₅₀ result have merit, but the paper would benefit from (1) tempered claims matching the actual evidence, (2) at least one GNN baseline comparison, (3) the Rosetta-pretrained model evaluated across all benchmarks, and (4) error bars on classification tasks. With these additions and an honest recalibration of claims, this could become a solid contribution.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>